Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

INDUSTRY × Hormone Refractory Prostate Cancer × Docetaxel × Clear all

Phase

Status

Sponsor Class

OTHER 3 INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Carcinoma, Non-Small-Cell Lung 172 Breast Neoplasms 118 Prostatic Neoplasms 64 Neoplasms 54 Neoplasm Metastasis 45 Lung Neoplasms 41 Stomach Neoplasms 22 Parkinson Disease 4, Autosomal Dominant Lewy Body 17 Squamous Cell Carcinoma of Head and Neck 14 Ovarian Neoplasms 14 Advanced Solid Tumors 13 Recurrence 12 Urinary Bladder Neoplasms 11 Carcinoma, Squamous Cell 10 Melanoma 9 Head and Neck Neoplasms 9 Colorectal Neoplasms 9 Esophageal Neoplasms 8 Carcinoma, Renal Cell 8 Solid Tumor 7 Esophageal Squamous Cell Carcinoma 7 Carcinoma, Transitional Cell 7 Carcinoma 7 Triple Negative Breast Neoplasms 6 Pancreatic Neoplasms 6 Neutropenia 6 HER2-positive Breast Cancer 6 Endometrial Neoplasms 6 Sarcoma 5 Prostatic Neoplasms, Castration-Resistant 5

Interventions

radium Ra 223 dichloride 2 gossypol acetic acid 1 bafetinib 1 Mycobacterium w vaccine 1 Docetaxel 1 Denosumab 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT00525408 2012-03-12

HRPC

Cadila Pharnmaceuticals

Phase 2 Terminated

Hormone Refractory Prostate Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡